TuHURA Biosciences Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
/ 
Frequently asked questions
To buy TuHURA Biosciences Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for TuHURA Biosciences Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for TuHURA Biosciences Inc. is HURA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
TuHURA Biosciences Inc. has its primary listing on NASDAQ (Small cap). You can trade TuHURA Biosciences Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, TuHURA Biosciences Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include TuHURA Biosciences Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like TuHURA Biosciences Inc..